Market Report, "South Africa Pharmaceuticals & Healthcare Report Q3 2010", published

Recently published research from Business Monitor International, "South Africa Pharmaceuticals & Healthcare Report Q3 2010", is now available at Fast Market Research
 
July 24, 2010 - PRLog -- BMI's Business Environment Ratings for the Middle East and Africa (MEA) pharmaceutical market underlines some of our key views for how the sector is performing in emerging markets. In particular we highlight Saudi Arabia, Egypt and Ghana as the most positive and promising, while the UAE and South Africa will continue as the main investment focuses. Ghana, newly added to our ratings, has entered at a respectable regional ranking of 15th out of 19. In MEA terms this is quite low, but in terms of our Sub- Saharan African market coverage only South Africa has a higher score, of 53.5 compared with Ghana's 39.1. Since South Africa benefits from a longer history of established health and social infrastructure and forms a base for most multinational drugmakers looking for an entrance point to Africa, its higher score is to be expected.

In June 2010, South Africa's Minister of Trade and Industry Rob Davies said the government welcomed Indian pharmaceutical companies establishing manufacturing units in the country. The invitation comes as part of the government's national industrial policy framework (NIPF), under which it offers a suite of incentives for various sectors, including the pharmaceutical sector. Davies said the pharmaceutical industry, which possesses an unexplored potential for development, would receive specific attention from the government.

Highlighting companies' interest in the South African generic medicines market, Indian drugmaker Ranbaxy Laboratories launched a generic form of Pfizer's blockbuster Lipitor (atorvastatin) in the country in June 2010, following the launch of the generic medicine in Canada in May. BMI believes the launch of the off-patent cholesterol drug in South Africa will provide Ranbaxy with significant revenue earning opportunities - atorvastatin has a market size of US$26.1mn and is the second most sold drug in South Africa after AstraZeneca's Nexium (esomeprazole). The Indian drugmaker's version of Lipitor, called Lipogen, will compete with the branded drug, which has a 33.2% share of the atorvastatin market in South Africa, and an authorised generic, Aspavor, which is sold by the Pfizer unit Pharmacia.

In May 2010, the South African government became the first to join the Pool for Open Innovation against Neglected Tropical Diseases, a programme with its initial focus on improving and developing new treatments against tuberculosis and malaria. The South African Technology Innovation Agency (TIA) stands to gain from knowledge transfer and access to patents, particularly in the biotechnology sector, which is still in the early stages of development. As the most developed Sub-Saharan African market, in terms of regulatory standards, market size and value, South Africa's entry into the patent pool should boost its attractiveness to multinational drugmakers looking at the country as a potential base for continental operations. Moreover, the South African drug market is expected to reach US$4.1bn by 2014, with prescription drugs accounting for 86%. Patented medicines will make up 58.5% of the total pharmaceutical market and still dominate in terms of value sales, even if generic drugs generate higher volume sales.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/74030_south_africa_pharmaceuti...

Partial Table of Contents:

Executive Summary
SWOT Analysis
- South Africa Pharmaceuticals And Healthcare Industry SWOT
- South Africa Political SWOT
- South Africa Economic SWOT
- South Africa Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Middle East And Africa Pharmaceutical Business Environment Ratings, Q310
- Limits To Potential Returns
- Risks To Realisation Of Returns
South Africa - Market Summary
Regulatory Regime
- Table: South Africa Drug Classification System (Section 22A of the Medicines and Related Substance Act 101 of 1965)
- Regulatory Developments
- Table: Proposed Scope Of The South African Health Products Regulatory Authority
- Pharmaceutical Advertising
- Intellectual Property Environment
- IP Developments
- Counterfeit Activity
- Pricing System
- Price Increases
- Pricing Developments
- Reimbursement System
Industry Developments
- Epidemiology
- HIV/AIDS
- Tuberculosis
- Healthcare Sector
- Healthcare Sector Developments
- Medical Tourism
- Private Healthcare Regulation
- National Health Reference Price List
- Health Insurance
- Government Health Insurance
- ARV Manufacturing And Government Tenders
- Pharmaceutical Sector Developments
- Retail Pharmacy Sector
- Research & Development Sector
- R&D Activities
- Vaccines
- Traditional African Medicine
- Medical Devices
- Table: South African Customs Classification Of Medical Devices
- Regional Developments In Medical Devices Sector
- Table: Aims Of PEPFAR-BD Partnership
Industry Forecast Scenario
- Overall Market Forecast
- Key Growth Factors - Industry
- Key Growth Factors - Macroeconomic
- Table: South Africa Economic Activity, 2007-2014
- Prescription Drug Market Forecast
- Patented Drug Market Forecast
- Generic Drug Market Forecast
- OTC Medicine Market Forecast
- Medical Device Market Forecast
- Pharmaceutical Trade Forecast
- Other Healthcare Data
- Key Risks To BMI's Forecast Scenario
Competitive Landscape
- Table: Private Market Size For Selected Products In South Africa (2007)
Company Profiles
- Indigenous Manufacturers
- Aspen Pharmacare
- Adcock Ingram
-

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=7403...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
End
Source: » Follow
Email:***@fastmr.com Email Verified
Zip:01267
Tags:Pharmaceutical, Drug, Healthcare, South African, Ratings, Generic, Medicine, Health, Medical, Regulatory
Industry:Health, Medical, Research
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share